1448309-95-2Relevant academic research and scientific papers
Iridinesulfonamide compound and use method thereof
-
, (2018/03/29)
An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically-acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation-induced cancers.
Discovery and structure-activity-relationship study of novel conformationally restricted indane analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors
Zheng, Qiangang,Tang, Shuai,Fu, Xianlei,Chen, Ziqi,Ye, Yan,Lan, Xiaojing,Jiang, Lei,Huang, Ying,Ding, Jian,Geng, Meiyu,Huang, Min,Wan, Huixin
supporting information, p. 5262 - 5266 (2017/10/30)
The discovery and optimization of various of indane amides as mutant IDH1 inhibitors via structure-based rational design were reported. The optimal compounds demonstrated both potent inhibition in IDH1R132H enzymatic activity and 2HG production in IDH1 mutant HT1080 cell line, favorable PK properties and great selectivity against IDH1wt and IDH2R140Q.
THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
-
Page/Page column, (2015/03/31)
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
-
Page/Page column, (2015/02/19)
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE
-
Page/Page column, (2013/07/31)
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
